TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $19 and keeps a Buy rating on the shares. The firm said the company delivered another nearly 50% year over year MRD growth quarter
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT: